AR
ARQT.US Arcutis Biotherapeutics Inc
- Market cap
- USD 3.57B
- P/E
- 122.9x
- P/B
- 14.27x
- ROE
- 6.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ARQT.US undervalued?
Graham numberThe Graham number of Arcutis Biotherapeutics Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Arcutis Biotherapeutics Inc fundamental analysis
No fundamental analysis for Arcutis Biotherapeutics Inc yet.
Arcutis Biotherapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company …
Full company profileArcutis Biotherapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Arcutis Biotherapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.69M | 59.6M | 197M | 376M | 506M |
| Gross Profit | - | - | -195K | -455K | -763K | 2.93M | 54.6M | 177M | 339M | 461M |
| Operating Income | -4.11M | -19.7M | -43.1M | -137M | -207M | -302M | -241M | -128M | -12.2M | 22.4M |
| EBITDA | -4.11M | -19.3M | -41.8M | -136M | -206M | -295M | -229M | -110M | 1.78M | 31.2M |
| Net Income | -4.98M | -19.3M | -42.0M | -136M | -206M | -311M | -262M | -140M | -16.1M | 16.7M |
| EPS | -4.71 | -0.53 | -1.10 | -3.80 | -4.17 | -5.66 | -3.78 | -1.16 | -0.13 | 0.12 |
| Balance Sheet | ||||||||||
| Total Assets | 3.82M | 51.1M | 107M | 298M | 408M | 449M | 341M | 349M | 433M | 524M |
| Total Liabilities | 8.81M | 75.1M | 5.55M | 27.6M | 110M | 240M | 253M | 191M | 243M | 280M |
| Shareholders' Equity | -4.99M | -24.0M | 101M | 271M | 298M | 210M | 88.7M | 158M | 189M | 244M |
| Cash & Short-term Investments | 3.42M | 50.9M | 101M | 284M | 389M | 410M | 272M | 228M | 221M | 259M |
| Total Debt | 966K | - | 307K | 4.96M | 77.6M | 203M | 206M | 111M | 6.27M | 115M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -3.78M | -14.1M | -42.8M | -113M | -175M | -258M | -247M | -112M | -5.63M | 45.0M |
| Capital Expenditure | 295K | 295K | 295K | 321K | 995K | 23.3M | 428K | 143K | 686K | 340K |
| Free Cash Flow | -3.78M | -14.1M | -43.1M | -113M | -176M | -281M | -247M | -112M | -6.31M | 44.7M |
| Ratios | ||||||||||
| ROE | - | - | -41.4% | -50.1% | -69.2% | -148.6% | -295.6% | -88.9% | -8.5% | 6.8% |
| ROA | -130.3% | -37.7% | -39.2% | -45.5% | -50.4% | -69.3% | -76.8% | -40.1% | -3.7% | 3.2% |
| Net Profit Margin | - | - | - | - | - | -8,449.8% | -439.8% | -71.3% | -4.3% | 3.3% |
| Debt to Equity | - | - | 0.00x | 0.02x | 0.26x | 0.97x | 2.32x | 0.70x | 0.03x | 0.47x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Arcutis Biotherapeutics Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 123M | 2.23 | - |
| 2021 | USD 72.4M | 1.46 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Arcutis Biotherapeutics Inc
- Insiders 1.80%
- Institutions 98.20%
- Public & others 0.00%
- Shares outstanding 126M
- Free float 94.6M
Top funds holding ARQT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 6.88M | 5.44% | -0.08% | Oct 2026 |
| Polar Capital Biotech S Inc | 6.26M | 4.95% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 3.59M | 2.84% | +0.36% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 3.24M | 2.56% | +2.69% | Oct 2026 |
| iShares Russell 2000 ETF | 2.90M | 2.29% | 0.00% | Oct 2026 |
| American Century Small Cap Growth Inv | 1.47M | 1.16% | 0.00% | Sep 2026 |
| MEDICAL BioHealth EUR Acc | 1.27M | 1.00% | +0.02% | Aug 2026 |
| Fidelity Small Cap Index | 1.25M | 0.99% | +0.15% | Aug 2026 |
| Oberweis Small-Cap Opportunities | 1.21M | 0.96% | 0.00% | Jun 2026 |
| iShares Russell 2000 Growth ETF | 1.07M | 0.85% | -0.38% | Oct 2026 |
| Candriam Eqs L Biotech C USD Cap | 1.06M | 0.83% | -2.88% | Apr 2026 |
| State Street SPDR Port S&P 600 Sm CpETF | 1.05M | 0.83% | -0.05% | Oct 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 1.03M | 0.81% | -0.23% | Oct 2026 |
| Franklin Biotechnology Discv A(acc)USD | 870K | 0.69% | 0.00% | Sep 2026 |
| Baron Discovery Institutional | 867K | 0.69% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 853K | 0.67% | -0.19% | Oct 2026 |
| PGIM Jennison Small Company A | 846K | 0.67% | 0.00% | Sep 2026 |
| Simplify Health Care ETF | 812K | 0.64% | +3.04% | Oct 2026 |
| Worldwide Healthcare Ord | 758K | 0.60% | 0.00% | Jul 2026 |
| Vanguard Russell 2000 ETF | 665K | 0.53% | +1.13% | Sep 2026 |
Top institutions holding ARQT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 12.4M | 9.89% | +0.89% | Jun 2026 |
| BlackRock Inc | 10.5M | 8.39% | +14.62% | Jun 2026 |
| Frazier Life Sciences Management, L.P. | 9.87M | 7.86% | 0.00% | Jun 2026 |
| Rubric Capital Management LP | 8.27M | 6.58% | 0.00% | Jun 2026 |
| Polar Capital Holdings PLC | 6.61M | 5.26% | +16.59% | Jun 2026 |
| State Street Corp | 5.82M | 4.63% | -7.52% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.99M | 3.97% | +2.41% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 4.45M | 3.54% | +5.50% | Jun 2026 |
| Jennison Associates LLC | 4.22M | 3.36% | -15.29% | Jun 2026 |
| D. E. Shaw & Co LP | 3.95M | 3.14% | +58.22% | Jun 2026 |
| UBS Group AG | 3.33M | 2.65% | +0.11% | Jun 2026 |
| Bank of America Corp | 2.99M | 2.38% | +34.49% | Jun 2026 |
| Geode Capital Management, LLC | 2.98M | 2.37% | -2.06% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 2.43M | 1.93% | +24.27% | Jun 2026 |
| Orbimed Advisors LLC | 2.04M | 1.62% | 0.00% | Jun 2026 |
| Franklin Templeton Inc | 1.93M | 1.54% | -15.97% | Jun 2026 |
| American Century Companies Inc | 1.93M | 1.53% | +31.56% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.67M | 1.33% | +4.08% | Jun 2026 |
| Jupiter Topco LLC | 1.41M | 1.12% | 0.00% | Jun 2026 |
| Oberweis Asset Management Inc | 1.37M | 1.09% | +0.51% | Jun 2026 |
Arcutis Biotherapeutics Inc company profile
- Company name
- Arcutis Biotherapeutics Inc
- Ticker
- ARQT.US
- Exchange
- USA Stocks
- Listed since
- Jan 31, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 354
- Fiscal year end
- December
- Address
- 3027 Townsgate Road, Westlake Village, CA, United States, 91361
- Phone
- 805 418 5006
- Website
- arcutis.com
About Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Arcutis Biotherapeutics Inc management
10- Mr. Todd Franklin Watanabe M.A.President, CEO & Director · born 1968
- Dr. Bhaskar Chaudhuri Ph.D.Co-Founder & Director Emeritus · born 1955
- Ms. Latha VairavanSenior VP & Chief Financial Officer · born 1978
- Mr. Masaru Matsuda Esq., J.D.Executive VP, Chief Legal Officer & Corporate Secretary · born 1971
- Dr. Patrick E. Burnett M.D., Ph.D.Executive VP & Chief Medical Officer · born 1972
- Mr. Brian SchoelkopfHead of Investor Relations
- Mr. Steve AriasVice President of Compliance & Privacy
- Ms. Amanda SheldonHead of Corporate Communications
- Ms. Aleen HosdaghianVice President of Marketing
- Mr. Todd TuckerSenior VP & Chief Human Resources Officer